Licensing

BALTIMORE — Lupin on Monday announced the appointment of Theresa Stevens as chief corporate development officer for its global operations. Stevens will assume full responsibility for global merger and acquisitions and specialty business strategy. Stevens has more than 27 years of experience in the pharmaceutical and biotech sector, with significant experience in managing strategy, corporate development, M&A and licensing.    

DUBLIN — Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending abbreviated new drug application beginning on April 1, 2015.

OXFORD, England  — Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

COCKEYSVILLE, Md. — Angelo Voxakis recently announced his retirement after 16 years as president and CEO of Epic Pharmacies, a national network of independently owned pharmacies, effective December 31. An executive search committee has been formed. 

SANTA FE, N.M. — Pharmacists in New Mexico have become the first in the United States certified to prescribe Narcan (naloxone), which prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension, according to a report published Wednesday by The New Mexican. 

MOUNT PROSPECT, Ill. — According to the National Association of Boards of Pharmacy, a Missouri bill would require health benefit plans to reimburse pharmacies when they dispense less than a 30-day supply for the purpose of synchronizing a patient’s chronic medications. 

NEW YORK — Recent research suggests that point-of-care testing for infectious diseases in community pharmacies could not only benefit patients but could also represent an opportunity for pharmacy as they look to strengthen their foothold along the front lines of health care.

DUBLIN — Actavis earlier this week announced that it has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (methylphenidate transdermal system). Daytrana is a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder.